

IP Lab

February 19, 2009

GENERIC'S ENVY, PATENT OWNER'S PRIDE: ROCHE'S 'VALCYTE' TRIUMPHS AT THE CHENNAI PATENT OFFICE

Dear All,

On January 1, 2005, the product patent regime in India was born again. In these few years of product patent regime, the Indian pharmaceutical industry has witnessed some tough battles in Indian courts and the four Patent Offices, between MNC patent holders and Indian generic drug manufacturers.

Roche's drug "**Valcyte**" (Valganciclovir hydrochloride) too has faced legal challenges. It met its pre-grant stage challenge in which it recently tasted victory at Chennai Patent Office, and is now facing post grant challenge. Roche has instituted infringement action against Cipla and is awaiting its hearing.

Please [click here for the document](#) tracing the journey of Valcyte in India and the hurdles it has met and will meet to survive as a valid patent in India.

IP-Pharma Team

Aditi Nadkarni / Gowree Gokhale

DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Unmasking Deepfakes

October 25, 2024

Are we ready for Designer Babies

October 24, 2024

Opportunities in GIFT City

October 18, 2024

Research Articles

Acquirers Beware: Indian Merger Control Regime Revamped!

September 15, 2024

Navigating the Boom: Rise of M&A in Healthcare

August 23, 2024

Navigating The Change in Shareholding and Management Rule for Non-Banking Financial Companies in India: A Practical Perspective

August 22, 2024

Audio

Renewable Roadmap: Budget 2024 and Beyond - Part I

August 26, 2024

Renewable Roadmap: Budget 2024 and Beyond - Part II

August 26, 2024

Renewable Roadmap: Budget 2024 and Beyond - Part III

August 26, 2024

NDA Connect

Connect with us at events, conferences and seminars.

NDA Hotline

[Click here to view Hotline archives.](#)

Video

"Investment return is not enough" Nishith Desai with Nikunj Dalmia (ET Now) at FI8 event in Riyadh

October 31, 2024

Analysing SEBI's Consultation Paper

on Simplification of registration for
FPIs

September 26, 2024

Scope of judicial interference and
inquiry in an application for
appointment of arbitrator under the
(Indian) Arbitration and Conciliation
Act, 1996

September 22, 2024